Among more than 2,300 patients with advanced chronic liver disease, a six-parameter algorithm, known as PLEASE, indicated that patients stratified as high risk had a cumulative risk of developing de ...

Gross classification guiding HCC therapy. (A) H&E staining of HCC tumour samples of all gross types. (B) The Kaplan-Meier curves of OS in patient with type IV HCC treated with or without TACE ...

Recent advancements in cancer immunotherapy have highlighted glypican-3 (GPC3) as a prominent target for treating hepatocellular carcinoma (HCC). However, approximately 10% to 30% of HCC patients ...

Hepatocellular carcinoma (HCC) is a primary liver cancer predominantly arising from chronic liver diseases such as hepatitis B and C infections, alcohol abuse, and metabolic disorders. It's one of the ...

SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received ...

Frontline setting accelerates potential for deep, durable responses in the treatment of liver cancers Study builds on clinical validation from one of the largest datasets in the in vivo CAR field ...